Publicaciones en colaboración con investigadores/as de Hospital Infanta Sofia (27)

2024

  1. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

    Journal of Clinical Medicine, Vol. 13, Núm. 5

  2. Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial

    Scientific Reports, Vol. 14, Núm. 1

  3. Demographic, functional and clinical characteristics in hip fracture patients according to mental status of Spanish National Hip Fracture Registry

    Revista Espanola de Geriatria y Gerontologia, Vol. 59, Núm. 3

  4. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica, Vol. 162, Núm. 10, pp. 470-476

  5. Unravelling the role of secretory Immnuoglobulin-A in COVID-19: a multicentre study in nursing homes during the first wave

    BMC geriatrics, Vol. 24, Núm. 1, pp. 804

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  3. POS0793-HPR Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 689.2-690

  4. Result of the update of the clinical pathway for hip fracture in the older adult at a university hospital in Madrid

    Revista Espanola de Geriatria y Gerontologia, Vol. 58, Núm. 2, pp. 61-67

  5. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

  6. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

    Vaccines, Vol. 11, Núm. 10

  7. Vitamin D deficiency and SARS-CoV-2 infection: A retrospective case–Control study with big-data analysis covering March 2020 to March 2021

    PLoS ONE, Vol. 18, Núm. 9 September

  8. Vitamin D deficiency and SARS‑CoV‑2 infection: A retrospective case-Control study with big-data analysis covering March 2020 to March 2021

    PloS one, Vol. 18, Núm. 9, pp. e0277388

2022

  1. Accuracy, feasibility and predictive ability of different frailty instruments in an acute geriatric setting

    European Geriatric Medicine, Vol. 13, Núm. 4, pp. 827-835

  2. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  3. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352

2021

  1. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients with Ankylosing Spondylitis

    Journal of Clinical Rheumatology, Vol. 27, Núm. 8, pp. E307-E311

  2. Storage proteins are driving pediatric hazelnut allergy in a lipid transfer protein-rich area

    Foods, Vol. 10, Núm. 10

2020

  1. AB0726 Choroidal Thickness Is a Biomarker a and Can Predict The Response to Treatment in Ankylosing Spondylitis

    Annals of the Rheumatic Diseases, Vol. 79, Núm. Suppl 1, pp. 1657.1-1658

  2. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis

    JCR: Journal of Clinical Rheumatology